KRAS and neoplasm: Understanding the mutational mechanisms of KRAS and delving into the role of different KRAS mutations in various tumor types present an intriguing challenge that can enhance our approach to agnostic therapies in oncology, with the inhibition of KRAS p.G12C serving as an example.